OSAM
CLDX icon

O'Shaughnessy Asset Management’s Celldex Therapeutics CLDX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,603
Closed -$141K – 1471
2021
Q3 		$141K Buy
2,603
+2,538
+3,905% +$119K ﹤0.01% 1204
2021
Q2 		$2K Hold
65
– – ﹤0.01% 2285
2021
Q1 		$1K Sell
65
-6
-8% -$138 ﹤0.01% 2149
2020
Q4 		$1K Buy
71
+54
+318% +$972 ﹤0.01% 1903
2020
Q3 		$0 Buy
+17
New +$199 ﹤0.01% 1884

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

O'Shaughnessy Asset Management's CLDX Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Celldex Therapeutics (CLDX) in Q4 2021, closing a stake of 2,603 shares — an estimated $141K sold.

O'Shaughnessy Asset Management first reported a position in CLDX in Q3 2020 and held it in 5 quarters. The position peaked at $141K in Q3 2021. 180 funds tracked by Wall St. Rank hold CLDX as of Q4 2021.

  • O'Shaughnessy Asset Management reported no remaining Celldex Therapeutics position as of Q4 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 2,603 Celldex Therapeutics shares in Q4 2021, an estimated $141K.
  • O'Shaughnessy Asset Management first reported a position in Celldex Therapeutics in Q3 2020 and held it in 5 quarters.
  • O'Shaughnessy Asset Management's Celldex Therapeutics position peaked at $141K in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.